Smart scans may boost prostate cancer radiation therapy
NCT ID NCT05924672
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether using PSMA PET scans to select patients with castration-resistant prostate cancer that has spread to bones can improve the effectiveness of radium-223 therapy. Radium-223 is a radioactive drug that targets bone tumors. The study involves only 2 participants and measures how many achieve a significant drop in PSA levels. The goal is to see if better patient selection leads to better outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Radium-223 (Ra-223)
- What this could lead to
- If successful, this could show that using PSMA PET scans to select patients leads to better tumor shrinkage with radium-223 therapy.
- What could go wrong
- This is a very small early-phase trial with only 2 participants, so results may not apply to larger groups. Radium-223 can cause bone marrow suppression and other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a three-drug cocktail outsmart resistant prostate cancer?
- Precision radiation may tame rising PSA after prostate surgery
- Real-Time nerve monitoring during spine surgery could predict bladder and bowel function
- Blood test could tell doctors when to stop prostate cancer treatment early
- Could a stronger first dose of targeted radiation beat back advanced prostate cancer?